Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial

MLA

Archana Rai, et al. “Empagliflozin Does Not Affect Left Ventricular Diastolic Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: Insight from the EMPA-HEART CardioLink-6 Randomized Clinical Trial.” Acta Diabetologica, vol. 59, no. 4, Aug. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d167950b4afa01a7a58f514e923febec&authtype=sso&custid=ns315887.

APA

Archana Rai, Kim A. Connelly, Subodh Verma, C. David Mazer, Hwee Teoh, Ming-Yen Ng, Idan Roifman, Adrian Quan, Marina Pourafkari, Laura Jimenez-Juan, Venkat Ramanan, Yin Ge, Djeven P. Deva, & Andrew T. Yan. (2021). Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. Acta Diabetologica, 59(4).

Chicago

Archana Rai, Kim A. Connelly, Subodh Verma, C. David Mazer, Hwee Teoh, Ming-Yen Ng, Idan Roifman, et al. 2021. “Empagliflozin Does Not Affect Left Ventricular Diastolic Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: Insight from the EMPA-HEART CardioLink-6 Randomized Clinical Trial.” Acta Diabetologica 59 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d167950b4afa01a7a58f514e923febec&authtype=sso&custid=ns315887.